Massive study pits popular Weight-Loss drugs against each other in heart health showdown
NCT ID NCT07096063
Summary
This study analyzed health insurance records of nearly 900,000 people to compare how well different diabetes and weight management drugs protect against serious heart problems. It specifically looked at tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) versus other common medications. The goal was to see which drug might be better at preventing heart attacks, strokes, and death in everyday patients with type 2 diabetes and overweight who are at risk for heart disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.